

Haas Ken
Form 4
November 30, 2010

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Haas Ken

(Last) (First) (Middle)

C/O ABINGWORTH
BIOVENTURES, 3000 SAND HILL
RD., B4-135

(Street)

MENLO PARK, CA 94025

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
ZOGENIX, INC. [ZGNX]

3. Date of Earliest Transaction
(Month/Day/Year)
11/29/2010

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/29/2010		C		901,363	A	<u>(1)</u>	901,363	I <u>(2)</u> <u>(4)</u> <u>(6)</u>	By Abingworth Bioventures IV LP
Common Stock	11/29/2010		C		535,643	A	<u>(1)</u>	1,437,006	I <u>(2)</u> <u>(4)</u> <u>(6)</u>	By Abingworth Bioventures IV LP
Common Stock	11/29/2010		C <u>(3)</u>		382,613	A	<u>(3)</u>	1,819,619	I <u>(2)</u> <u>(4)</u> <u>(6)</u>	By Abingworth Bioventures

Common Stock	11/29/2010	P	495,750	A	\$ 4	2,315,369	I (2) (4) (6)	IV LP By Abingworth Bioventures IV LP
Common Stock	11/29/2010	C	7,727	A	<u>(1)</u>	7,727	I (3) (4) (6)	By Abingworth Bioventures IV Executives L.P.
Common Stock	11/29/2010	C	4,592	A	<u>(1)</u>	12,319	I (3) (4) (6)	By Abingworth Bioventures IV Executives L.P.
Common Stock	11/29/2010	C ⁽³⁾	3,280	A	<u>(3)</u>	15,599	I (3) (4) (6)	By Abingworth Bioventures IV Executives L.P.
Common Stock	11/29/2010	P	4,250	A	\$ 4	19,849	I (3) (4) (6)	By Abingworth Bioventures IV Executives L.P.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares

Edgar Filing: Haas Ken - Form 4

Series A-2 Convertible Preferred Stock	<u>(1)</u>	11/29/2010	C	9,013,631	<u>(1)</u>	<u>(1)</u>	Common Stock	901,36
Series B Convertible Preferred Stock	<u>(1)</u>	11/29/2010	C	5,356,437	<u>(1)</u>	<u>(1)</u>	Common Stock	535,64
8% Convertible Promissory Note	<u>(5)</u>	11/29/2010	C <u>(5)</u>	382,613	<u>(5)</u>	<u>(5)</u>	Common Stock	382,61
Series A-2 Convertible Preferred Stock	<u>(1)</u>	11/29/2010	C	77,278	<u>(1)</u>	<u>(1)</u>	Common Stock	7,727
Series B Convertible Preferred Stock	<u>(1)</u>	11/29/2010	C	45,930	<u>(1)</u>	<u>(1)</u>	Common Stock	4,592
8% Convertible Promissory Note	<u>(5)</u>	11/29/2010	C <u>(5)</u>	3,280	<u>(5)</u>	<u>(5)</u>	Common Stock	3,280

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Haas Ken C/O ABINGWORTH BIOVENTURES 3000 SAND HILL RD., B4-135 MENLO PARK, CA 94025	X			

Signatures

/s/ Ken Haas 11/29/2010

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each of the Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock automatically converted to Common Stock at the closing of the Issuer's initial public offering on November 29, 2010 at a conversion ratio one share of Common Stock for every ten shares of Series A-2 Convertible Preferred Stock and one share of Common Stock for every ten shares of Series B Convertible Preferred Stock, as applicable, rounded down to the next whole number, for no additional consideration.

(2) These securities are owned of record by Abingworth Bioventures IV LP ("AB IV").

(3) These securities are owned of record by Abingworth Bioventures IV Executives L.P. ("AB IV Executives")

Abingworth Management Ltd. ("AM Ltd.") serves as investment manager of each of AB IV and AB IV Executives and may be deemed to share voting and dispositive power with respect to the securities owned by AB IV and AB IV Executives. The Reporting Person is a (4) venture partner of Abingworth Management, Inc., and in such capacity may be deemed to beneficially own the securities owned of record by AB IV and AB IV Executives, but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

The principle of the Note and accrued interest thereon was automatically converted upon the closing of the Issuer's initial public offering (5) on November 29, 2010 into shares of Common Stock at a conversion price equal to \$4.00 per share, the per share price of the Common Stock sold in the Issuer's initial public offering.

(6) The filing of this statement shall not be deemed an admission that, for the purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Person is the beneficial owner of equity securities covered by this statement

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.